{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-022964","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2021-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.147352+00:00","generated_at":"2026-06-29T03:06:19.103732+00:00","sec_items":["2.01","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enveric completes MagicMed acquisition; issues 9.95M shares (~31.7% ownership)","bullets":["Enveric issued 9,951,237 shares to MagicMed shareholders, representing ~31.7% of combined company.","Enveric received ~$4 million CAD cash from MagicMed treasury at closing.","Dr. Joseph Tucker (ex-MagicMed CEO) appointed CEO of Enveric; David Johnson becomes Executive Chairman.","Dr. Peter Facchini appointed Chief Scientific Officer; Dr. Jillian Hagel appointed Chief Technology Officer.","Board expanded from 5 to 7; Tucker and Brad Thompson joined as directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-022964","json":"https://secwatch.observer/filing/0001493152-21-022964.json","markdown":"https://secwatch.observer/filing/0001493152-21-022964.md","text":"https://secwatch.observer/filing/0001493152-21-022964.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/0001493152-21-022964-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T03:06:19.103732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0658f0822c","claim":"Dr. Jillian Hagel was appointed as Chief Technology Officer at Enveric Biosciences, Inc..","evidence_excerpt":"the Company appointed each of (i) Dr. Tucker, 53, (ii) Dr. Peter Facchini, 58 and (iii) Dr. Jillian Hagel, 43, to be Chief Executive Officer, Chief Scientific Officer and Chief Technology Officer, respectively","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/0001493152-21-022964-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Technology Officer"}],"fact_type":"executive_change"},{"claim_id":"30daa760db","claim":"Dr. Joseph Tucker was appointed as Director at Enveric Biosciences, Inc..","evidence_excerpt":"the Company appointed each of (i) Dr. Joseph Tucker, who served as president and chief executive officer, and as a director, of MagicMed immediately prior to the Effective Time and (ii) Brad Thompson, who served as a director of MagicMed immediately prior to the Effective Time, to the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/0001493152-21-022964-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4ca6e843c2","claim":"David Johnson changed role as Executive Chairman at Enveric Biosciences, Inc..","evidence_excerpt":"assigned David Johnson, 63, the title of Executive Chairman of the Company, and removed the title of Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/0001493152-21-022964-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"assigned"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"d2529108b8","claim":"Brad Thompson was appointed as Director at Enveric Biosciences, Inc..","evidence_excerpt":"the Company appointed each of (i) Dr. Joseph Tucker, who served as president and chief executive officer, and as a director, of MagicMed immediately prior to the Effective Time and (ii) Brad Thompson, who served as a director of MagicMed immediately prior to the Effective Time, to the Company’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/0001493152-21-022964-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"daff2fe0e5","claim":"Dr. Peter Facchini was appointed as Chief Scientific Officer at Enveric Biosciences, Inc..","evidence_excerpt":"the Company appointed each of (i) Dr. Tucker, 53, (ii) Dr. Peter Facchini, 58 and (iii) Dr. Jillian Hagel, 43, to be Chief Executive Officer, Chief Scientific Officer and Chief Technology Officer, respectively","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/0001493152-21-022964-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"f996fcc591","claim":"Dr. Joseph Tucker was appointed as Chief Executive Officer at Enveric Biosciences, Inc..","evidence_excerpt":"the Company appointed each of (i) Dr. Tucker, 53, (ii) Dr. Peter Facchini, 58 and (iii) Dr. Jillian Hagel, 43, to be Chief Executive Officer, Chief Scientific Officer and Chief Technology Officer, respectively","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/0001493152-21-022964-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}